BioSpace News Archive

The latest corporate intelligence studies report that the global cold plasma market is anticipated to grow commendably over the forecast years, registering a lucrative growth rate of 15 % over the forecast years i.e. 2021 to 2026.

The global fallopian tube cancer market has been growing in tandem with improvements in cancer research and development activities.

The global spatial genomics and transcriptomics market was initially evaluated at US$ 626.9 million in the base year of the study i.e. 2020.

Acupath Labs and UroGPO announced in April a partnership to make URO17® available to the UroGPO membership nationwide.

Pharming Group N.V. announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022.

Evelo Biosciences, Inc. presented biomarker data demonstrating the broad anti-inflammatory effects of EDP1815, the Company’s lead product candidate in inflammation, in a Phase 2 clinical trial in psoriasis.

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its financial and business update for the six-month period ending June 30, 2022.

Alzinova AB, announces that a second external safety review has been carried out of the Company’s clinical phase 1b study - with a positive assessment to continue the study as planned.

Inivata, a leader in liquid biopsy, alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease and recurrence at the European Society for Medical Oncology Congress, taking place on 9-13 September 2022.

Vektor Medical, the developer of the world’s first technology to rapidly map cardiac arrhythmias using only 12-lead ECG data, today announced Circulation: Arrhythmia and Electrophysiology has published a peer-reviewed manuscript of the clinical data from a study evaluating the accuracy of its vMap® technology.